Cholestasis ofpregnancy is associated with increased fetal morbidity and mortality and should be treated actively. The significance attached to pruritus in pregnancy is often minimal, but it is a cardinal symptom of cholestasis of pregnancy, which may have no other clinical features. Eight women with previous cholestasis of pregnancy were referred to The Liver Unit within a 12 month period for advice concerning future pregnancies. Thirteen pregnancies had been affected by cholestasis of pregnancy and 12 had been treated expectantly with resultant perinatal morbidity or mortality in 11 (one normal delivery), including; eight stillbirths, two premature deliveries with fetal distress (one died in perinatal period), and an emergency caesarean section for fetal distress. The other pregnancy was treated actively and delivery was uncomplicated. Subsequently, three of these cases with recurrent cholestasis of pregnancy were referred while pregnant. In each, cholestasis developed with severe pruritus, gross increase of serum bile acids, and deranged liver tests. Each was treated with the choleretic agent ursodeoxycholic acid, with rapid clinical improvement and resolution of deranged biochemistry. In conclusion, cholestasis of pregnancy continues to be treated expectantly despite its association with increased morbidity and mortality and evidence suggesting improved prognosis with active treatment and the potential of reducing the associated perinatal mortality. In an uncontrolled series of three patients with cholestasis of pregnancy, ursodeoxycholic acid seemed to provide safe and effective therapy. (Gut 1995; 37: 580-584) 
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Cholestasis of pregnancy is a disease of unknown aetiology, which may cause severe and intractable pruritus. The maternal prognosis is excellent, with symptoms and biochemical derangements resolving rapidly post partum, but cholestasis of pregnancy is associated with significant fetal morbidity and mortality.'-9 Cholestasis of pregnancy typically develops during the third trimester of pregnancy, but occasionally presents before 20 weeks. By definition, dermatological disease should be absent, if a diagnosis is made on clinical criteria alone,9 but this is not necessary if biochemical evidence of cholestasis is obtained. Most patients are not jaundiced and many have normal standard liver function tests. Serum alanine transaminase (ALT) is the most sensitive of the conventional liver function tests,10-12 although serum bile acids are invariably increased.0" 11 13 Symptoms vary from mild pruritus to intractable pruritus, associated with gastrointestinal upset and icterus. Symptoms almost invariably resolve within one week of delivery.
Treatment of cholestasis of pregnancy varies widely. Despite evidence to the contrary, some obstetricians still perceive cholestasis of pregnancy as a benign condition and adopt an expectant policy. We report eight cases with a history of cholestasis of pregnancy whose pregnancies had mostly been treated conservatively. Three of these cases were pregnant at the time of referral and treated with the choleretic ursodeoxycholic acid.
Case reports and previous obstetric histories ( 
Progress
Case 1 Figure 1 is a diagrammatic representation of serum AST, pruritus score, and serum bile acids. The first trimester was normal. S-adenosyl-L-methionine 1600 mg daily, was started orally at 16 weeks as prophylaxis, even though liver function tests and serum bile acids were normal. Dyspepsia and diarrhoea developed, so the dose was reduced to 1200 mg daily. Despite S-adenosyl-L-methionine, pruritus developed at 25 weeks gestation. Liver function tests remained normal, but serum bile acid concentrations were increased. At 29 weeks, pruritus became increasingly severe and serum AST became abnormal. Intravenous S-adenosyl-L-methionine, 1200 mg daily, was started, but AST continued to rise -213 IU/l (<30 IU/l) and pruritus became more troublesome. She was admitted to hospital for close monitoring. At 31 weeks, Sadenosyl-L-methionine was stopped and UDCA was started at 750 mg daily, by mouth. The first and second trimesters were normal. Pruritus developed at 30 A study of 18 patients from Vancouver1 recorded fetal distress in 33/3% and meconium staining in 58%. These authors,1 and others3 19 recommended delivery when evidence of lung maturity has been established, although early delivery is not without morbidity. Shaw reported 59% morbidity in their intervention group. 1 Some authors report fetal prognosis to correlate with disease severity.2 820 In a prospective study of 1 17 patients with cholestasis of pregnancy, Laatikainen8 reported concentrations of serum bile acids to be a more sensitive predictor of fetal distress than standard liver function tests, so that women with highest serum bile acid concentrations should be subjected to more intensive monitoring. Even in mild or moderate cases, however, fetal risk was still noted.8 Biochemical markers of fetoplacental function, oestriol, and human placental lactogen, have proved ineffective at predicting fetal distress.21 22 Development of the optimal treatment policy in cholestasis of pregnancy is hindered by difficulty predicting fetal outcome. The stillborn babies in the cases we report showed no evidence of dysmaturity, suggesting that chronic nutritional deficiency was not present and all but one of the fetal deaths occurred at, or beyond, 37 weeks gestation. These findings are in accordance with previous reports, in which most stillbirths occurred late in pregnancy.2 6 22-24 34 We have reported on eight women with cholestasis of pregnancy associated with eight stillbirths, a perinatal death, and two potential 'near misses'. We suggest there is a causal relation between cholestasis of pregnancy and the stillbirths, although this cannot be proved. Cholestasis of pregnancy causes distressing symptoms and is associated with significant increases in fetal morbidity and mortality. The aim of this report is to highlight the condition, which we consider to be commonly under recognised and inappropriately treated.
Its recognition is essential if early diagnosis is to permit timely fetal surveillance and intervention. Most stillbirths occur at or just before term. Elective delivery when fetal lung maturity is established could prevent the vast majority of such fetal loss. Appropriate obstetric treatment in cholestasis of pregnancy therefore represents a potential means by which perinatal mortality can be reduced.
UDCA, in a small, uncontrolled series seems effective at improving biochemical abnormalities and symptoms. Whether this would influence morbidity and mortality associated with the condition is unknown. These biochemical and clinical end points should be measured in controlled trials. 
